Previous Close | 0.1500 |
Open | 0.1500 |
Bid | 0.0500 |
Ask | 0.2500 |
Strike | 7.50 |
Expire Date | 2024-08-16 |
Day's Range | 0.1500 - 0.1500 |
Contract Range | N/A |
Volume | |
Open Interest | 5.85k |
VANCOUVER, Wash. and NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL. Absci management is scheduled to present on Monday, June 10th at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website
Explore key financial outcomes, strategic partnerships, and innovative developments from Absci Corp's first quarter of 2024.
Initiated IND-enabling studies for ABS-101 in February Continuing to advance ABS-201 and ABS-301 through preclinical studies VANCOUVER, Wash. and NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended March 31, 2024. "During the first quarter, we made significant strides in advancing both our internal and partnered programs according to plan," said Sean McC